Authors and Disclosures
Marius Trøseid1,2*†, José R. Arribas3,4†, Lambert Assoumou5, Aleksander Rygh Holten2,6, Julien Poissy7,8, Vida Terzić9,10, Fulvia Mazzaferri11, Jesús Rodríguez Bano12–14, Joe Eustace15, Maya Hites16,17, Michael Joannidis18, José-Artur Paiva19,20, Jean Reuter21, Isabel Püntmann22, Thale D. J. H. Patrick-Brown23,2, Elin Westerheim24, Katerina Nezvalova-Henriksen25, Lydie Beniguel5, Tuva Børresdatter Dahl26,27, Maude Bouscambert28, Monika Halanova29, Zoltán Péterfi30, Sotirios Tsiodras31,32, Michael Rezek33, Matthias Briel34, Serhat Ünal35, Martin Schlegel36, Florence Ader37,38, Karine Lacombe39,40, Cecilie Delphin Amdal41, Serge Rodrigues5, Kristian Tonby42,2, Alexandre Gaudet43,44, Lars Heggelund45,46, Joy Mootien47, Asgeir Johannessen2,48, Jannicke Horjen Møller49, Beatriz Diaz Pollan50,51, Anders Aune Tveita52, Anders Benjamin Kildal53, Jean-Christophe Richard54,55, Olav Dalgard56,2, Victoria Charlotte Simensen57, Aliou Baldé5, Lucie de Gastines9,10, Marta del Álamo58, Burç Aydin59, Fridtjof Lund-Johansen59, Mary-Anne Trabaud60, Alpha Diallo9,10, Bente Halvorsen61,2, John-Arne Røttingen62, Evelina Tacconelli63,11†, Yazdan Yazdanpanah64,65†, Inge C. Olsen66† and Dominique Costagliola5†, EU SolidAct study group
1Section for Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway. 2Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 3Infectious Diseases Unit, Internal Medicine Department, La Paz University Hospital, IdiPAZ, Madrid, Spain. 4Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain. 5Sorbonne Université, INSERM, Institut Pierre Louis d'Épidemiologie Et de Santé Publique (IPLESP), Paris, France. 6Department of Acute Medicine, Oslo University Hospital, Oslo, Norway. 7Lille University, Lille, France/CHU Lille - Hôpital Roger Salengro, Lille, France. 8L'Institut National de La Santé Et de La Recherche Médicale (Inserm), Paris, France. 9Maladies Infectieuses Emergentes, 75015 Paris, France. 10Institut National de La Santé Et de La Recherche Médicale, INSERM, 75013 Paris, France. 11Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. 12Department of Medicine, Virgen Macarena University Hospital, Seville, Spain. 13University of Sevilla and Biomedicines Institute of Seville (IBiS)/CSIC, Seville, Spain. 14CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain. 15University College Cork, Cork, Ireland. 16Brussels University Hospital-Erasme, Brussels, Belgium. 17Université Libre de Bruxelles, Brussels, Belgium. 18Medical University Innsbruck, Innsbruck, Austria. 19Intensive Care Medicine Department, Centro Hospitalar Universitário Sao Joao, Porto, Portugal. 20Faculty of Medicine, University of Porto, Porto, Portugal. 21Centre Hospitalier de Luxembourg, Service de Réanimation-Soins Intensifs, 1210 Luxembourg, Luxembourg. 22Institute of Pharmacology, Hospital Group Gesundheit Nord gGmbH, Bremen, Germany. 23Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital, Oslo, Norway. 24Section for Monitoring, Clinical Trial Unit (CTU), Oslo University Hospital, Oslo, Norway. 25Department of Haematology, Oslo University Hospital and Oslo Hospital Pharmacy, Oslo, Norway. 26Research Institute for Internal Medicine, Oslo University Hospital, Oslo, Norway. 27Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway. 28Laboratoire de Virologie, Institut Des Agents Infectieux de Lyon, Centre National de Reference Des Virus Des Infections Respiratoires France Sud, Hospices Civils de Lyon, 69317 Lyon, France. 29Department of Epidemiology, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Košice, Slovakia. 301St Department of Internal Medicine, Division of Infectology, University of Pécs, Pécs, Hungary. 31National and Kapodistrian University of Athens, Athens, Greece. 32University Hospital of Athens Attikon, Athens, Greece. 33St. Anne University Hospital, Brno, Czech Republic. 34Swiss Clinical Trial Organisation and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland. 35Hacettepe University Hospital, Ankara, Turkey. 36Department of Anesthesiology and Intensive Care Medicine, Klinikum Rechts Der Isar, Technische Universität München, Munich, Germany. 37Hospices Civils de Lyon, Département Des Maladies Infectieuses Et Tropicales, 69004 Lyon, France. 38Centre International de Recherche en Infectiologie (CIRI), Inserm 1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, 69007 Lyon, France. 39Sorbonne Université, Institut Pierre-Louis d'Épidemiologie Et de Santé Publique, INSERM, 75013 Paris, France. 40APHP, Hôpital Saint-Antoine, Service de Maladies Infectieuses Et Tropicales, 75012 Paris, France. 41Research support service and Department of Oncology, Oslo University Hospital, Oslo, Norway. 42Deptartment of Infectious Diseases, Oslo University Hospital, Oslo, Norway. 43Critical Care Center, Department of Intensive Care Medicine, CHU Lille, 59000 Lille, France. 44Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d'Infection Et d'Immunité de Lille, 59000 Lille, France. 45Medical Department, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway. 46Department of Clinical Science, University of Bergen, Bergen, Norway. 47Service, de Réanimation Médiale, GHRMSA Hopital Emile Muller, Mulhouse, France. 48Department of Infectious Diseases, Vestfold Hospital Trust, Tønsberg, Norway. 49Department of Intensive Care Medicine, Stavanger University Hospital, Stavanger, Norway. 50Infectious Diseases Unit, Internal Medicine Department, La Paz University Hospital, Madrid, Spain. 51Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), IdiPAZ, Madrid, Spain. 52Department of Medicine, Barum Hospital, Vestre Viken, Bærum, Norway. 53Department of Anesthesiology and Intensive Care, University Hospital of North Norway, Tromsø, Norway. 54Service de Medecine Intensive-Réanimation, Hôpital de La Croix - Rousse - HCL, Lyon, France. 55CREATIS INSERM U1206-CNRS UMR 5220, Lyon, France. 56Akershus University Hospital, Lørenskog, Norway. 57Division of Health Services, Department of Global Health, Norwegian Institute of Public Health, Oslo, Norway. 58ECRIN, Paris, France. 59Department of Immunology, Oslo University Hospital, Oslo, Norway. 60Laboratoire de Virologie, Institut Des Agents Infectieux de Lyon, Centre National de Reference Des Virus Respiratoires France Sud, 69317 Hospices Civils de LyonLyon, France. 61Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway. 62Norwegian Institute of Public Health, Oslo, Norway. 63Verona University Hospital, Verona, Italy. 64Université de Paris, IAME, INSERM, 75018 Paris, France. 65AP-HP, Hôpital Bichat, Service de Maladies Infectieuses Et Tropicales, 75018 Paris, France. 66Department of Research Support for Clinical Trials, Oslo University Hospital, Oslo, Norway.
*Correspondence
Marius Troseid marius.troseid@medisin.uio.no
Author contributions
The trial protocol was designed by MT, ICO, JAR, DC, JRA, AD, VT, LdG, and LA with contribution from other members of the writing committee and Eli Lilly. YY, JAR, MT, ICO, ET, JP and DC obtained funding for the study. LA, LB, AB, and SR were responsible for the data management, and AD, VT, and LdG for the pharmacovigilance. MB, MAT, FL-J, BH, and TBD were responsible for the virological and serological analysis, and biobanking. The SAP was written by LA and approved by MT, DC, JRA, and ICO. AB and LA performed the statistical analysis. This manuscript was drafted by MT, JRA, LA, ARH, JP, VT, ICO, and DC. ICO, LA, AB and DC had full access to the data. All members of the writing committee edited the manuscript for important intellectual content. All authors gave final approval of the version to be published and had final responsibility for the decision to submit for publication.
Competing interests
MT has been member of scientific advisory board for Lilly. JRA has received advisory fees from Lilly. JP reports lecture fees from Gilead; support for attending meetings from Gilead, Eumedica, Merck Sharp & Dohme, outside the submitted work. ARH reports personal fee from Pfizer (2021) for lectures outside the submitted work. MH(it) has received funding for other trials on COVID-19 from the Federal Belgian Center for Knowledge and the joint Université Libre de Bruxelles-Fonds Erasme-COVID-19 projects (2020–21), personal fees from Gilead (2020) and Pfizer (2021) for editing and lectures outside the submitted work, and travel/congress grants from Pfizer (2020, 2021), and Gilead (2022). MJ reports consulting or speakers fees from Baxter, Gilead, CLS Behring, AM-Pharma, Novartis, Fresenius and grant support from Fresenius, Baxter, outside the submitted work. JAP reports fees for lectures and advisory boards from MSD, Pfizer, Astra-Zeneca, Jansen, Gilead, AOP Orphan Pharmaceuticals, Cepheid MB reports an unrestricted grant for Moderna (2022) outside the submitted work. MB reports an unrestricted grant for Moderna (2022) outside the submitted work. KL reports personal fees from Gilead, MSD, Janssen and ViiV Healthcare for advisory boards and lectures outside of the submitted work. JM reports personal fees from Pfizer (2017) for lectures outside the submitted work and travel fees from Pfizer (2022) and Menarini (2021). JCR reports a grant from Hamilton medical (2019–2020) outside the submitted work. FLJ reports Helse Sør-Øst grant for developing COVID-19 serology (2020–2021) and Grant from CEPI to monitor responses in patients (2021–2023). DC reports an HIV grant from Janssen (2019–2020), personal fees from Gilead (2020) and Pfizer (2022) for lectures outside the submitted work. All other authors have nothing to declare.